Skip to content

The Spleen in Sickle Cell Anemia and Sickle Cell Thalassemia

The Spleen in Sickle Cell Anemia and Sickle Cell Thalassemia. Clinical Presentation and Follow up. Splenectomy, Indications and Complications.

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00971698
Enrollment
50
Registered
2009-09-04
Start date
2009-02-28
Completion date
2010-08-31
Last updated
2011-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sickle Cell Anemia, Thalassemia

Keywords

Splenectomy, Thrombocytosis, Infections, Spleen, Sickle Cell Thalassemia

Brief summary

The spleen in Sickle Cell Anemia and Sickle Cell Thalassemia is usually enlarged in the first years of life but the immune protection provided is considered insufficient. In homozygous Sickle cell patients the spleen usually developed recurrent infarcts and after the first decade of age become fibrotic. Acute splenic sequestration is also frequent in those patients and this is considered as an indication for splenectomy. In comparison in Sickle cell thalassemia patients, hypersplenism is more frequent. The purpose of this study is to compare the clinical and laboratory issues related to the spleen in two groups of Sickle cell patients.

Detailed description

Clinical and laboratory characteristics related to the spleen in SCA patients will be studied. Two groups of patient will be compared, a group of Sickle cell patients (Homozygous) and a second group of patients with Sickle cell beta thalassemia. In those patients that splenectomy was performed the incidence of infections will be recorded besides the indications for splenectomy and the incidence of thrombotic events or thrombocytosis.

Interventions

None listed

Sponsors

HaEmek Medical Center, Israel
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
1 Years to 35 Years
Healthy volunteers
No

Inclusion criteria

* All the patients followed up at the Pediatric Hematology Unit

Exclusion criteria

* Patients lost from follow up of with insufficient data

Design outcomes

Primary

MeasureTime frame
Clinical events and abnormal laboratory resultsOne year

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026